Livestock geneticists, including Curt Van Tassell of the USDA Agricultural Research Service, worked with Illumina to develop GoldenGate Indexing and are now working on a custom panel for screening livestock. Replacing older methods will allow livestock screening labs to better access genetic information of value. For example, breeders use SNP data to identify DNA markers for applications such as identifying parentage and economically important traits, including disease resistance, marbling, and feed efficiency. With Illumina’s new GoldenGate Indexing, researchers will have a higher degree of multiplexing options at a cost they can afford.
“Both livestock and crop researchers have a vested interest in adopting low-plex, high-sample throughput genotyping as a more efficient method for screening. GoldenGate Indexing offers genetic laboratories the opportunity to expand their existing efforts in molecular breeding with a low-cost, fully automated system for fixed and custom content studies,” said Joel McComb, senior vice president and general manager of Illumina’s Life Sciences business unit.
The Illumina GoldenGate Assay is a flexible, pre-optimized assay providing consistent, high-quality genotyping results. GoldenGate Indexing leverages this proven technology by evolving it into a high-sample throughput solution with fully integrated automation and sample tracking capabilities.
GoldenGate Indexing represents only one aspect of Illumina’s broad portfolio of genetic analysis tools for human and agricultural research. Illumina’s array and sequencing-based technologies support the industry’s broadest range of genetic analysis applications. For more information, please visit http://www.illumina.com/goldengateindexing.
About Illumina
Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of next-generation life-science tools and integrated systems for the analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery and clinical research, allow diseases to be detected earlier, and permit better choices of drugs for individual patients.
